Kangmei Pharmaceutical Co., Ltd. (SHA:600518)
1.360
+0.020 (1.49%)
Aug 10, 2026, 3:00 PM CST
Kangmei Pharmaceutical Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 5,033 | 5,252 | 5,189 | 4,874 | 4,180 | 4,153 |
Revenue Growth | -4.81% | 1.22% | 6.46% | 16.60% | 0.66% | -23.27% |
Gross Profit Gross Profit Growth | 951.36 | 948.5 | 653.37 | 728.86 | 431.14 | 91.52 |
Operating Income Operating Income Growth | -251.88 | -221.55 | -413.53 | 179.59 | -1,040 | -3,046 |
Net Income Net Income Growth | -14.74 | 10.33 | 8.57 | 102.52 | -2,688 | 7,918 |
Earnings Per Share EPS Growth | -0.00 | 0.00 | 0.00 | 0.01 | -0.19 | 0.57 |
EPS Growth | - | 16.67% | -94.00% | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Traditional Chinese Medicine, Western Medicine and Medical Devices Traditional Chinese Medicine, Western Medicine and Medical Devices Growth | 4,219 | 4,241 | 3,876 | 3,434 | 3,407 |
Health Food and Food Health Food and Food Growth | 500.27 | 437.48 | 502.79 | 324.58 | 184.23 |
Property Leasing and Sales and Others Property Leasing and Sales and Others Growth | 532.62 | 510.55 | 494.89 | 421.95 | 560.99 |
Total Total Growth | 5,252 | 5,189 | 4,874 | 4,180 | 4,153 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,229 | 1,240 | 977.92 | 1,057 | 1,508 | 2,419 |
Total Debt Total Debt Growth | 173.71 | 184.36 | 139.13 | 255.01 | 263.87 | 205.29 |
Net Cash (Debt) Net Cash Growth | 1,055 | 1,056 | 838.8 | 801.68 | 1,244 | 2,214 |
Net Cash Growth | 41.14% | 25.87% | 4.63% | -35.54% | -43.82% | - |
Net Cash Per Share Net Cash Per Share Growth | 0.06 | 0.07 | 0.06 | 0.08 | 0.09 | 0.16 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 157.98 | 111.35 | -427.63 | -317.52 | -749.96 | 214.21 |
Capital Expenditures CapEx Growth | -225.48 | -217.06 | -61.71 | -99.74 | -48.12 | -171.63 |
Free Cash Flow Free Cash Flow Growth | -67.5 | -105.71 | -489.34 | -417.27 | -798.08 | 42.58 |
Free Cash Flow Growth | - | - | - | - | - | -94.16% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 18.90% | 18.06% | 12.59% | 14.95% | 10.31% | 2.20% |
Operating Margin | -5.00% | -4.22% | -7.97% | 3.69% | -24.89% | -73.37% |
Pretax Margin | 0.33% | 0.82% | 0.67% | 2.26% | -63.73% | 196.39% |
Profit Margin | -0.29% | 0.20% | 0.17% | 2.10% | -64.31% | 190.68% |
FCF Margin | -1.34% | -2.01% | -9.43% | -8.56% | -19.09% | 1.03% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | 2557.44 | 3783.85 | 251.53 | - | 5.41 |
Forward PE | - | 2.56 | 2.56 | 2.56 | 2.56 | 2.56 |
P/FCF Ratio | - | - | - | - | - | 1006.12 |
PS Ratio | 3.68 | 5.03 | 6.25 | 5.29 | 7.30 | 10.32 |